In an interview with PharmaShots, Mark Manfredi, President, and CEO at Ikena Oncology shared his views on the US FDA’s IND clearance of IK-930 for the treatment of solid tumors that harbors genetic alterations in the hippo pathwayShots:The US FDA has accepted its IND application to initiate the P-I study of IK-930 for solid tumors harboring genetic alterations in the…
